Primary organ-specific lymphoma

Primary organ-specific lymphoma refers to a group of rare lymphomas that arise primarily within a specific organ other than the lymph nodes, spleen, or bone marrow. These are extranodal lymphomas that develop and predominantly involve a single organ such as the brain (primary central nervous system lymphoma), thyroid, breast, lung, liver, kidney, adrenal gland, prostate, or other sites. The disease is characterized by the localized proliferation of malignant lymphocytes within the affected organ, often presenting with symptoms related to that organ's dysfunction, such as a mass, pain, or organ-specific impairment. Constitutional symptoms including fever, night sweats, and weight loss (B symptoms) may also be present but are less common than in systemic lymphomas. The majority of primary organ-specific lymphomas are of B-cell origin, most commonly diffuse large B-cell lymphoma (DLBCL), though other histological subtypes including marginal zone lymphoma and follicular lymphoma may occur depending on the organ involved. Diagnosis typically requires tissue biopsy with histopathological examination, immunohistochemistry, and staging investigations to confirm that the disease is confined primarily to the organ of origin. Imaging studies such as CT and PET-CT scans are essential for staging and ruling out widespread disease. Treatment approaches vary depending on the specific organ involved, the histological subtype, and the stage of disease. Standard therapies generally include chemotherapy (often R-CHOP or similar regimens containing rituximab for B-cell lymphomas), radiation therapy, or a combination of both. For certain sites such as the central nervous system, specialized regimens using high-dose methotrexate-based chemotherapy are employed due to the blood-brain barrier. Surgical resection may play a role in select cases. Prognosis varies widely depending on the organ of origin, histological subtype, stage at diagnosis, and patient factors. These lymphomas are considered rare overall, and management is best guided by multidisciplinary teams with expertise in lymphoma treatment.

Common questions about Primary organ-specific lymphoma